RemeGen (9995) released an announcement detailing proposed arrangements for day-to-day related party transactions from 2026 to 2028 and amendments to several internal governance policies. According to the announcement, these plans will be submitted for consideration at the third extraordinary general meeting (EGM), scheduled for December 2, 2025, in Yantai.

RemeGen outlined the renewal of existing service and lease agreements related to continuing connected transactions, involving entities such as MabPlex, Yeda Incubation, RC Pharma, and Kangkang. These include various framework agreements for research and development services, property leases, materials procurement, and clinical coordination services. The announcement highlights expected transaction caps based on demand projections and prior usage data. The company emphasizes that these arrangements aim to maintain normal business operations and regulatory compliance.

The announcement further provides a series of proposals to amend certain governance policies, including management guidelines for related transactions, external guarantees, external investments, and raised proceeds. The proposed amendments reflect updated regulatory requirements and underscore RemeGen’s goal of strengthening internal oversight and optimizing resource allocation.

Shareholders are invited to review and vote on these proposals at the EGM. Interested parties can reference the announcement for additional details on the underlying agreements, proposed caps, and the specific revisions to internal policies. The EGM will be held at the company’s Phase III Building in Yantai at 2:00 p.m. on December 2, 2025.